Linked research, clinical, and regulatory source pathways.
Company profile
About Varian Medical Systems
Varian Medical Systems, now part of Siemens Healthineers, is a pioneering medical device and software company focused on elevating cancer care across the entire patient journey. With decades of experience in radiation oncology, Varian develops and delivers comprehensive solutions that span radiosurgery, radiotherapy, adaptive therapy, brachytherapy, imaging for radiotherapy, interventional oncology, and theranostics. The company's product portfolio includes advanced treatment delivery systems like Edge, Halcyon, and TrueBeam; treatment planning software including Eclipse and AI-powered tools like AI-Rad Companion; and comprehensive oncology information systems such as ARIA CORE. Varian's technology serves radiation oncologists, medical physicists, dosimetrists, and oncology care teams worldwide, enabling precise, personalized cancer treatment. The company's vision centers on enhancing the patient experience, streamlining clinical workflows, making innovation accessible, and enabling personalized care. Through its Advanced Oncology Solutions division, Varian also provides clinical services, professional services, and managed services to optimize operations. The company supports veterinary oncology and has expanded into interventional oncology through its integration with Siemens Healthineers, offering cryoablation, embolization, and microwave ablation solutions. Varian's comprehensive approach integrates hardware, software, and services to help build a world without fear of cancer.
Company description Varian Medical Systems official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Varian Medical Systems?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Brain metastases
- Cancer (all types)
- Conditions requiring interventional oncology procedures
- Prostate cancer
- Various solid tumors treated with radiation therapy
Who it serves
- Academic Medical Centers
- Cancer Centers
- Health Systems
- Hospitals
- Radiation Oncology Clinics
- Veterinary Hospitals
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: ARIA CORE, Eclipse, HyperSight, Interoperability across Varian product ecosystem, Velocity.
Geographic context
MarketsAustralia · Brazil · Canada · China · Finland · France · Germany · Global · Japan · Latin America · Netherlands · Portugal · Spain · Switzerland · Turkey · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Integration with Siemens Healthineers expanding into interventional radiology and interventional oncology, launch of ARIA CORE for Theranostics, RapidArc Dynamic transformation in planning and delivery, NAEOTOM Alpha.Prime RT Pro Edition CT benchmark
Partnerships
Recorded partners
- CHRISTUS Health (Advanced Oncology Solutions case study partner)
- Siemens Healthineers (parent company)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Dynamic modulated arc therapy (DMAT): A time-aware, modulation-steered optimization framework for next-generation radiotherapy delivery.Journal of applied clinical medical physics · Sep 1, 2026
Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG).Clinical and translational radiation oncology · Sep 1, 2026
Should reference beam data be used for beam modeling during linear accelerator commissioning?Medical physics · Jul 1, 2026
Dosimetric evaluation and clinical feasibility of Halcyon-E O-ring linear accelerator for single fraction coplanar stereotactic radiosurgery.Journal of medical imaging and radiation sciences · Jul 1, 2026
An integrated toolkit for structure generation, optimization, and evaluation in spatially fractionated radiation therapy.Journal of applied clinical medical physics · Jul 1, 2026
Establishment of local diagnostic reference levels for planning CT in adult and pediatric radiotherapy patients in 18 Japanese university hospitals.Radiological physics and technology · Jun 1, 2026
Clinical validation
Clinical-trial records
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueNCT05837767 · Sponsor · RECRUITING
Ovarian-Sparing Adaptive Radiotherapy in Young Adult WomenNCT06904365 · Sponsor · RECRUITING
Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION TrialNCT06995053 · Sponsor · ACTIVE NOT RECRUITING
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade GliomaNCT06108206 · Sponsor · ACTIVE NOT RECRUITING
Radiation Therapy for the Treatment of Metastatic Gastrointestinal CancersNCT04221893 · Sponsor · RECRUITING
Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung CancerNCT05785845 · Sponsor · COMPLETED
Regulatory
Regulatory records
syngo.via RT Image Suite VC10K252304 · 510k · Mar 18, 2026
Ethos Treatment Management (3.0); Ethos Treatment Planning (2.0)K232923 · 510k · Apr 30, 2024
AI SegmentationK211881 · 510k · Sep 2, 2021
AI SegmentationK203469 · 510k · Apr 19, 2021
Ethos Treatment Management, Ethos Treatment Planning, Ethos Radiotherapy System, HalcyonK192377 · 510k · Feb 10, 2020
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
High-quality OAR contours
AI-Rad Companion Organs RT using state-of-the-art AI algorithms
Precise treatment delivery
Real-time tracking and motion management
Streamlined clinical workflows
Integrated software and hardware solutions
Personalized care
Adaptive therapy accounting for patient changes
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Varian Medical Systems
Recent articles published on Varian Medical Systems's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.